Is erdafitinib effective against cholangiocarcinoma? Clinical research data and patient feedback

Erdafitinib is a targeted therapy drug that mainly treats cancer by inhibiting the fibroblast growth factor receptor (FGFR) signaling pathway. Although it was originally approved to treat advanced or metastatic urothelial carcinoma (UC), clinical studies in recent years have shown that erdafitinib is also potentially effective in some patients with cholangiocarcinoma who carry specific genetic mutations. Especially in patients with cholangiocarcinoma with FGFR gene abnormalities (such as FGFR2 gene fusion or other mutations), erdafitinib has shown a significant therapeutic effect.

In a clinical trial for advanced cholangiocarcinoma, researchers found that after FGFR gene fusion-positive cholangiocarcinoma patients were treated with erdafitinib, some patients' tumors shrank significantly, and some patients achieved partial response (PR). In addition, studies have shown that erdafitinib can significantly extend progression-free survival (PFS) and overall survival (OS), especially in patients who have failed standard chemotherapy. Compared with traditional chemotherapy, erdafitinib provides a more targeted treatment option with a more dramatic response to specific molecular abnormalities.

In terms of patient feedback, cholangiocarcinoma patients using erdafitinib generally report more positive therapeutic effects, especially in those with FGFR2 gene mutations. Many patients say that erdafitinib can effectively relieve their condition, improve symptoms, and improve their quality of life. However, some patients experience side effects of the drug, such as eye discomfort (dry eyes, blurred vision), rashes, mouth ulcers, etc. These side effects can generally be managed by adjusting drug dosage or taking symptomatic treatment, and are generally tolerated by patients.

Although erdafitinib has shown certain efficacy in the treatment of cholangiocarcinoma, its treatment is suitable for a relatively specific population, mainly targeting FGFR mutation-positive patients. Therefore, before using erdafitinib, doctors will perform genetic testing to determine whether the patient is a candidate for treatment with the drug. Overall, erdafitinib provides a new option for personalized treatment of cholangiocarcinoma, especially when traditional treatments are ineffective or resistant, bringing hope to patients.

Reference link:https://www.balversa.com/